Professional Marketing briefs: October 2013

Share this article:
Professional Marketing briefs: October 2013
Professional Marketing briefs: October 2013
San Antonio-based Mission Pharmacal has created a new sales force to promote its line of urology medicines. A company announcement noted that the new lineup is a revival of the days when it used to have distinct urology and women's healthcare sales forces. The urology-only reps are a mix of now-former Women's Health/Urology reps and newly onboarded team members.

Lundbeck is readying a staff of more than 200 sales reps in anticipation of regulatory approval of its anti-depressant ­Brintellix, reports Bloomberg. Denmark's second-biggest drug maker could not share details regarding whether these will be in-house or contract reps, but a Takeda spokesperson tells MM&M the co-promote agreement with Takeda will leverage Lundbeck's experience working with CNS HCPs and Takeda's foundation in primary care. The FDA is scheduled to vote on the drug by October 2.

Boehringer Ingelheim is cutting jobs abroad, and sales roles are part of the headcount. PMLive reports that the company is eliminating 143 sales positions, the majority of the 178 jobs that are being cut as part of the reorganization. The remaining 35 jobs are administrative roles.


Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?